Adarx Pharmaceuticals (ADRX) closed at $17.00 on October 30, 2026, down 4.8% from the previous close, on volume of 525,982 shares (30-day average 690,336).
Data as of October 30, 2026.
Russell 2000 estimated to add 107 stocks in December rebalance - Stephens
Seeking Alpha News (Thu, 29-Oct 3:12 PM ET)
Globe Newswire (Thu, 1-Oct 4:15 PM ET)
Adarx Pharmaceuticals Inc is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Its pipeline includes three clinical-stage programs and two advanced preclinical programs. The three hepatic-targeted programs are agazisiran, onvuzosiran, and ADX-626, while the two extrahepatic-targeted programs are ADX-077 and ADX-199.
Adarx Pharmaceuticals trades on the NASDAQ stock market under the symbol ADRX.
As of November 2, 2026, ADRX stock price declined to $16.12 with 210,969 million shares trading.
ADRX has a market cap of $1.72 billion. This is considered a Small Cap stock.
The top ETF exchange traded funds that ADRX belongs to (by Net Assets): VTI, VXF, VTWO, VTWG, VTWV.
ADRX support price is $16.23 and resistance is $17.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADRX shares will trade within this expected range on the day.
